Wwedbush raised its price target on shares of Anacor Pharmaceuticals Inc. (ANAC) Friday morning to $20 from $10. Anacor reported positive results from a Phase 2 dose-ranging trial of its topical boron-based phosphodiesterase-4 inhibitor, AN2728 on Thursday.
Anacor Pharmaceuticals gapped open higher Friday and has spiked to the upside in early trade. The stock is now up 1.69 at $6.53 on above average volume and has surged to a 5-month high.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.